ARS Pharmaceuticals, Inc.
SPRY • NASDAQ
ARS Pharmaceuticals, Inc. is a biotechnology company in the healthcare sector trading on NASDAQ, led by CEO Richard E. Lowenthal, with a market cap of $801.3M.
CEORichard E. Lowenthal
Next Earnings
Upcoming earnings announcement for ARS Pharmaceuticals, Inc.
Date
Wednesday, May 13, 2026 (in a month)
Timing
Before Market Open (7:00 AM New York)
Fiscal Period
Q1 2026
EPS Estimate
-$0.52
Revenue Estimate
$23.3M
Earnings History
Past 12 earnings reports for ARS Pharmaceuticals, Inc.
| Date | Period | EPS | EPS Surprise | Revenue | Rev. Surprise | Filing |
|---|---|---|---|---|---|---|
| Mar 9, 2026 | Q4 2025 | -$0.42Est: -$0.46 | +8.7% | $28.1MEst: $25.6M | +9.5% |  10-K |
| Nov 10, 2025 | Q3 2025 | -$0.52Est: -$0.47 | -10.6% | $32.5MEst: $28.6M | +13.6% | 10-Q |
| Aug 13, 2025 | Q2 2025 | -$0.46Est: -$0.47 | +2.1% | $15.7MEst: $14.3M | +9.8% | 10-Q |
| May 14, 2025 | Q1 2025 | -$0.35Est: -$0.36 | +2.8% | $8.0MEst: $7.5M | +6.6% | 10-Q |
| Mar 20, 2025 | Q4 2024 | $0.48Est: -$0.12 | +500.0% | $86.6MEst: $15.9M | +444.7% | 10-K |
| Nov 13, 2024 | Q3 2024 | -$0.20Est: -$0.15 | -33.3% | $2.1MEst: $560.0K | +269.3% | 10-Q/A |
| Aug 6, 2024 | Q2 2024 | -$0.13Est: -$0.12 | -8.3% | $500.0KEst: $1.0M | -50.0% | 10-Q |
| May 9, 2024 | Q1 2024 | -$0.11Est: -$0.11 | 0.0% | - | — | 10-Q |
| Mar 21, 2024 | Q4 2023 | -$0.07Est: -$0.14 | +50.0% | - | — | 10-K |
| Nov 9, 2023 | Q3 2023 | -$0.16 | — | - | — | — |
| Aug 10, 2023 | Q2 2023 | -$0.18Est: -$0.17 | -5.9% | $10.0K | — | — |
| May 15, 2023 | Q1 2023 | -$0.16Est: -$0.17 | +5.9% | $20.0K | — | — |